Status:

WITHDRAWN

RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM

Lead Sponsor:

Temple University

Conditions:

Cytokine Storm

SARS-CoV-2

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The primary aim of this study is to test whether Doxycycline can benefit patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections by inhibiting the replication of the viru...

Detailed Description

This study will randomize 20 patients with confirmed or highly suspected early stage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to Doxycycline (100 mg BID) or Placebo and then assess...

Eligibility Criteria

Inclusion

  • Confirmed or highly suspected early stage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disease with clinical suspicion score \>6/20, not requiring hospitalization
  • Age ≥18 years
  • Willing to sign the informed consent form
  • Willing to take study drug or placebo as directed for 21 days

Exclusion

  • Confirmed or highly suspected early stage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disease with clinical suspicion score \>6/20, requiring hospitalization
  • Suspected or confirmed convalescent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), within the prior 4 weeks
  • Age \<18 years' old
  • Inability to take medications orally
  • Inability to provide written consent
  • Known sensitivity/allergy to doxycycline or tetracyclines
  • Current use of doxycycline for another indication
  • Pregnancy
  • A known diagnosis of myasthenia gravis
  • History of Clostridium Difficile infection within past 12 months
  • Sun sensitivity
  • Individuals using medications which could lower doxycycline levels, including barbiturates, phenytoin, carbamazepine, warfarin
  • Individuals using isotretinoin

Key Trial Info

Start Date :

June 22 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 13 2021

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04433078

Start Date

June 22 2020

End Date

April 13 2021

Last Update

April 19 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Temple University Hospital

Philadelphia, Pennsylvania, United States, 19140